426 Developing a Molecular Toolkit to define NEK functions in triple-negative breast cancer (TNBC) biology

Objectives/Goals: The never in mitosis kinase (NEK) family regulates vital processes, namely cell cycle progression, but their potential as therapeutic targets in TNBC has not been fully explored. Our studies aim to develop a toolkit to investigate the functional roles of NEKs in pathologies includi...

Full description

Saved in:
Bibliographic Details
Main Authors: Julia Boehling, Jack R. Elliot, Elizabeth C. Martin, Bridgette M. Collins-Burow, David H. Drewry, Van T. Hoang, Sean Lee, Matthew E. Burow
Format: Article
Language:English
Published: Cambridge University Press 2025-04-01
Series:Journal of Clinical and Translational Science
Online Access:https://www.cambridge.org/core/product/identifier/S2059866124010331/type/journal_article
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849393771017404416
author Julia Boehling
Jack R. Elliot
Elizabeth C. Martin
Bridgette M. Collins-Burow
David H. Drewry
Van T. Hoang
Sean Lee
Matthew E. Burow
author_facet Julia Boehling
Jack R. Elliot
Elizabeth C. Martin
Bridgette M. Collins-Burow
David H. Drewry
Van T. Hoang
Sean Lee
Matthew E. Burow
author_sort Julia Boehling
collection DOAJ
description Objectives/Goals: The never in mitosis kinase (NEK) family regulates vital processes, namely cell cycle progression, but their potential as therapeutic targets in TNBC has not been fully explored. Our studies aim to develop a toolkit to investigate the functional roles of NEKs in pathologies including carcinogenesis. Methods/Study Population: To assess differential NEK expression in normal and tumor tissues and correlation of gene expression with patient survival, we used Gene Expression Profiling Interactive Analysis (GEPIA) and Kaplan–Meier Plotter (KMPlot) pan-cancer analysis, respectively. Basal NEK protein levels were determined by immunoblot across a panel of cell lines, including breast cancer, osteosarcoma, hepatocellular carcinoma, and non-cancerous cells, to identify appropriate systems for evaluation of NEK function. Doxycycline-inducible cell lines were generated by transduction with lentiviral stocks of NEK shRNA and overexpression constructs and antibiotic selection. Expression was analyzed by qPCR and immunoblot. Results/Anticipated Results: Expression of NEK2, 4, 5, 6, 8, and 11 was higher in breast tumors compared to normal tissue by GEPIA analysis. Further examination using KMPlot showed a correlation between elevated NEK6 expression and decreased overall survival in patients with aggressive cancers. As an initial proof-of-concept study, we analyzed NEK6 protein expression in breast cancer cells. Levels of NEK6 were elevated in TNBC cells (MDA-MB-231) compared to hormone receptor positive (HR+) breast cancer cells (MCF7). Using complementary approaches to investigate the functional role of NEK6 in breast cancer, we depleted NEK6 expression using shRNAs in TNBC cells and expressed NEK6 in HR+ cells Discussion/Significance of Impact: Because kinase dysregulation promotes oncogenesis and metastasis, targeting kinases is a key strategy in therapeutic development. A NEK-specific molecular toolkit allows researchers to elucidate NEK functions and contributions to carcinogenesis, promoting advancement of novel therapies.
format Article
id doaj-art-a54c8324cf9a4cdcbb50d1b20f0502f7
institution Kabale University
issn 2059-8661
language English
publishDate 2025-04-01
publisher Cambridge University Press
record_format Article
series Journal of Clinical and Translational Science
spelling doaj-art-a54c8324cf9a4cdcbb50d1b20f0502f72025-08-20T03:40:18ZengCambridge University PressJournal of Clinical and Translational Science2059-86612025-04-01912812810.1017/cts.2024.1033426 Developing a Molecular Toolkit to define NEK functions in triple-negative breast cancer (TNBC) biologyJulia Boehling0Jack R. Elliot1Elizabeth C. Martin2Bridgette M. Collins-Burow3David H. Drewry4Van T. Hoang5Sean Lee6Matthew E. Burow7Department of Medicine, Section of Hematology and Oncology, Tulane University, New Orleans, LADepartment of Medicine, Section of Hematology and Oncology, Tulane University, New Orleans, LA Tulane Cancer Center, Tulane Univeristy School of Medicine, New Orleans, LADepartment of Medicine, Section of Hematology and Oncology, Tulane University, New Orleans, LA Tulane Cancer Center, Tulane Univeristy School of Medicine, New Orleans, LADepartment of Medicine, Section of Hematology and Oncology, Tulane University, New Orleans, LA Tulane Cancer Center, Tulane Univeristy School of Medicine, New Orleans, LAUNC Lineberger Comprehensive Cancer Center, School of Medicine, UNC at Chapel Hill, Chapel Hill, NCDepartment of Medicine, Section of Hematology and Oncology, Tulane University, New Orleans, LA Tulane Cancer Center, Tulane Univeristy School of Medicine, New Orleans, LADepartment of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, LADepartment of Medicine, Section of Hematology and Oncology, Tulane University, New Orleans, LA Tulane Cancer Center, Tulane Univeristy School of Medicine, New Orleans, LAObjectives/Goals: The never in mitosis kinase (NEK) family regulates vital processes, namely cell cycle progression, but their potential as therapeutic targets in TNBC has not been fully explored. Our studies aim to develop a toolkit to investigate the functional roles of NEKs in pathologies including carcinogenesis. Methods/Study Population: To assess differential NEK expression in normal and tumor tissues and correlation of gene expression with patient survival, we used Gene Expression Profiling Interactive Analysis (GEPIA) and Kaplan–Meier Plotter (KMPlot) pan-cancer analysis, respectively. Basal NEK protein levels were determined by immunoblot across a panel of cell lines, including breast cancer, osteosarcoma, hepatocellular carcinoma, and non-cancerous cells, to identify appropriate systems for evaluation of NEK function. Doxycycline-inducible cell lines were generated by transduction with lentiviral stocks of NEK shRNA and overexpression constructs and antibiotic selection. Expression was analyzed by qPCR and immunoblot. Results/Anticipated Results: Expression of NEK2, 4, 5, 6, 8, and 11 was higher in breast tumors compared to normal tissue by GEPIA analysis. Further examination using KMPlot showed a correlation between elevated NEK6 expression and decreased overall survival in patients with aggressive cancers. As an initial proof-of-concept study, we analyzed NEK6 protein expression in breast cancer cells. Levels of NEK6 were elevated in TNBC cells (MDA-MB-231) compared to hormone receptor positive (HR+) breast cancer cells (MCF7). Using complementary approaches to investigate the functional role of NEK6 in breast cancer, we depleted NEK6 expression using shRNAs in TNBC cells and expressed NEK6 in HR+ cells Discussion/Significance of Impact: Because kinase dysregulation promotes oncogenesis and metastasis, targeting kinases is a key strategy in therapeutic development. A NEK-specific molecular toolkit allows researchers to elucidate NEK functions and contributions to carcinogenesis, promoting advancement of novel therapies.https://www.cambridge.org/core/product/identifier/S2059866124010331/type/journal_article
spellingShingle Julia Boehling
Jack R. Elliot
Elizabeth C. Martin
Bridgette M. Collins-Burow
David H. Drewry
Van T. Hoang
Sean Lee
Matthew E. Burow
426 Developing a Molecular Toolkit to define NEK functions in triple-negative breast cancer (TNBC) biology
Journal of Clinical and Translational Science
title 426 Developing a Molecular Toolkit to define NEK functions in triple-negative breast cancer (TNBC) biology
title_full 426 Developing a Molecular Toolkit to define NEK functions in triple-negative breast cancer (TNBC) biology
title_fullStr 426 Developing a Molecular Toolkit to define NEK functions in triple-negative breast cancer (TNBC) biology
title_full_unstemmed 426 Developing a Molecular Toolkit to define NEK functions in triple-negative breast cancer (TNBC) biology
title_short 426 Developing a Molecular Toolkit to define NEK functions in triple-negative breast cancer (TNBC) biology
title_sort 426 developing a molecular toolkit to define nek functions in triple negative breast cancer tnbc biology
url https://www.cambridge.org/core/product/identifier/S2059866124010331/type/journal_article
work_keys_str_mv AT juliaboehling 426developingamoleculartoolkittodefinenekfunctionsintriplenegativebreastcancertnbcbiology
AT jackrelliot 426developingamoleculartoolkittodefinenekfunctionsintriplenegativebreastcancertnbcbiology
AT elizabethcmartin 426developingamoleculartoolkittodefinenekfunctionsintriplenegativebreastcancertnbcbiology
AT bridgettemcollinsburow 426developingamoleculartoolkittodefinenekfunctionsintriplenegativebreastcancertnbcbiology
AT davidhdrewry 426developingamoleculartoolkittodefinenekfunctionsintriplenegativebreastcancertnbcbiology
AT vanthoang 426developingamoleculartoolkittodefinenekfunctionsintriplenegativebreastcancertnbcbiology
AT seanlee 426developingamoleculartoolkittodefinenekfunctionsintriplenegativebreastcancertnbcbiology
AT mattheweburow 426developingamoleculartoolkittodefinenekfunctionsintriplenegativebreastcancertnbcbiology